TY - JOUR
T1 - Acute and Postacute Clinical Characteristics of Coronavirus Disease 2019 in Children in Japan
AU - Katsuta, Tomohiro
AU - Aizawa, Yuta
AU - Shoji, Kensuke
AU - Shimizu, Naoki
AU - Okada, Kenji
AU - Nakano, Takashi
AU - Kamiya, Hajime
AU - Amo, Kiyoko
AU - Ishiwada, Naruhiko
AU - Iwata, Satoshi
AU - Oshiro, Makoto
AU - Okabe, Nobuhiko
AU - Korematsu, Seigo
AU - Suga, Shigeru
AU - Tsugawa, Takeshi
AU - Nishimura, Naoko
AU - Hishiki, Haruka
AU - Fujioka, Masashi
AU - Hosoya, Mitsuaki
AU - Mizuno, Yumi
AU - Miyairi, Isao
AU - Miyazaki, Chiaki
AU - Morishima, Tsuneo
AU - Yoshikawa, Tetsushi
AU - Wada, Taizo
AU - Ouchi, Kazunobu
AU - Moriuchi, Hiroyuki
AU - Tanaka-Taya, Keiko
AU - Saitoh, Akihiko
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Background: The clinical features of coronavirus disease 2019 (COVID-19) in children have been changing because of the emergence and rapid spread of variants of concern (VOC). The increase in cases infected with VOC has brought concern with persistent symptoms after COVID-19 in children. This survey aimed to analyze the clinical manifestations and persistent symptoms of pediatric COVID-19 cases in Japan. Methods: We analyzed the clinical manifestations of pediatric COVID-19 cases reported between February 2020 and April 2022 in Japan, using a dedicated database updated voluntarily by the members of the Japan Pediatric Society. Using the same database, we also analyzed persistent symptoms after COVID-19 in children who were diagnosed between February 2020 and November 2021. Results: A total of 5411 and 1697 pediatric COVID-19 cases were included for analyzing clinical manifestations and persistent symptoms, respectively. During the Omicron variant predominant period, the percentage of patients with seizures increased to 13.4% and 7.4% in patient groups 1-4 and 5-11 years of age, respectively, compared with the pre-Delta (1.3%, 0.4%) or Delta period (3.1%, 0.0%). Persistent and present symptoms after 28 days of COVID-19 onset were reported in 55 (3.2%). Conclusions: Our survey showed that the rate of symptomatic pediatric COVID-19 cases increased gradually, especially during the Omicron variant predominant period, and a certain percentage of pediatric cases had persistent symptoms. Certain percentages of pediatric COVID-19 patients had severe complications or prolonged symptoms. Further studies are needed to follow such patients.
AB - Background: The clinical features of coronavirus disease 2019 (COVID-19) in children have been changing because of the emergence and rapid spread of variants of concern (VOC). The increase in cases infected with VOC has brought concern with persistent symptoms after COVID-19 in children. This survey aimed to analyze the clinical manifestations and persistent symptoms of pediatric COVID-19 cases in Japan. Methods: We analyzed the clinical manifestations of pediatric COVID-19 cases reported between February 2020 and April 2022 in Japan, using a dedicated database updated voluntarily by the members of the Japan Pediatric Society. Using the same database, we also analyzed persistent symptoms after COVID-19 in children who were diagnosed between February 2020 and November 2021. Results: A total of 5411 and 1697 pediatric COVID-19 cases were included for analyzing clinical manifestations and persistent symptoms, respectively. During the Omicron variant predominant period, the percentage of patients with seizures increased to 13.4% and 7.4% in patient groups 1-4 and 5-11 years of age, respectively, compared with the pre-Delta (1.3%, 0.4%) or Delta period (3.1%, 0.0%). Persistent and present symptoms after 28 days of COVID-19 onset were reported in 55 (3.2%). Conclusions: Our survey showed that the rate of symptomatic pediatric COVID-19 cases increased gradually, especially during the Omicron variant predominant period, and a certain percentage of pediatric cases had persistent symptoms. Certain percentages of pediatric COVID-19 patients had severe complications or prolonged symptoms. Further studies are needed to follow such patients.
KW - COVID-19
KW - clinical characteristics
KW - pediatrics
KW - postacute
KW - severity
UR - https://www.scopus.com/pages/publications/85148678090
UR - https://www.scopus.com/inward/citedby.url?scp=85148678090&partnerID=8YFLogxK
U2 - 10.1097/INF.0000000000003792
DO - 10.1097/INF.0000000000003792
M3 - Article
C2 - 36730047
AN - SCOPUS:85148678090
SN - 0891-3668
VL - 42
SP - 240
EP - 246
JO - Pediatric Infectious Disease Journal
JF - Pediatric Infectious Disease Journal
IS - 3
ER -